eCite Digital Repository

Variation in plasma levels of glucosamine with chronic dosing: a possible reason for inconsistent clinical outcomes in osteoarthritis

Citation

Asthana, C and Peterson, GM and Shastri, M and Jones, G and Patel, R, Variation in plasma levels of glucosamine with chronic dosing: a possible reason for inconsistent clinical outcomes in osteoarthritis, Clinical Therapeutics, 42, (8) pp. e140-e149. ISSN 0149-2918 (2020) [Refereed Article]

Copyright Statement

2020 Elsevier Inc.

DOI: doi:10.1016/j.clinthera.2020.06.009

Abstract

Purpose: Glucosamine is widely used by patients with osteoarthritis (OA) to provide symptomatic relief and to delay disease progression. However, clinical studies have reported inconsistent clinical outcomes. The current study hypothesized that the reported inconsistent clinical results could be, in part, due to variable bioavailability and elimination of glucosamine. This study therefore aimed to determine steady-state minimum plasma concentrations (Css min) of glucosamine to examine the variability among patients taking the supplement.

Methods: Patients with OA who had been taking glucosamine for at least 1 week were recruited. Patients' blood samples were collected 24 h after the ingestion of the previous dose to determine Observed Css min and after a 5-day washout period to determine the endogenous glucosamine levels (GlcNend). The Actual Css min was calculated by using the following equation: Actual Css min = Observed Css min GlcNend. The glucosamine plasma concentrations were determined by using a previously developed HPLC method.

Findings: Ninety-one participants (age range, 4289 years; mean [SD] age, 68.2 [7.6] years) were recruited (70% females). There was substantial (106-fold) variation, with a 45% coefficient of variation, between the Actual Css min levels (3320 ng/mL) in participants. No significant association of Actual Css min was observed with various dose- and patient-related variables.

Implications: The observed high variability in steady-state plasma concentrations indicates substantial inter-patient differences in the absorption and elimination of glucosamine, which could be a cause for inconsistent clinical outcomes in patients with OA.

Item Details

Item Type:Refereed Article
Keywords:glucosamine, osteoarthritis, pharmacokinetics, plasma concentration, variability
Research Division:Biomedical and Clinical Sciences
Research Group:Pharmacology and pharmaceutical sciences
Research Field:Clinical pharmacology and therapeutics
Objective Division:Health
Objective Group:Clinical health
Objective Field:Clinical health not elsewhere classified
UTAS Author:Asthana, C (Mrs Chhavi Asthana)
UTAS Author:Peterson, GM (Professor Gregory Peterson)
UTAS Author:Shastri, M (Mr Madhur Shastri)
UTAS Author:Jones, G (Professor Graeme Jones)
UTAS Author:Patel, R (Dr Rahul Patel)
ID Code:140827
Year Published:2020
Web of Science® Times Cited:2
Deposited By:Pharmacy
Deposited On:2020-09-10
Last Modified:2021-05-31
Downloads:0

Repository Staff Only: item control page